Derm Topics

From Biologics to Oral Therapies: An Overview of Hidradenitis Suppurativa Medical Treatment

Navigating the multifactorial pathophysiology of hidradenitis suppurativa (HS) requires a nuanced balance of medical and procedural therapies. Fortunately, dermatologists have more options than ever to help patients gain control over this historically difficult-to-treat condition. At the 2026 ODAC Dermatology Conference, Dr. Steven Daveluy, MD, FAAD, Program Director and Professor of Dermatology at Wayne State University School of Medicine, offered his clinical insights on current HS management—sharing actionable tips for everything from flare control to combination regimens.

Dr. Daveluy pointed out that the first step to treating is assessing the morphology and severity. Certain strategies align better with active/inflammatory HS versus inactive/non-inflammatory HS. Inflammation is treated with medical therapy whereas tunnels, scars/contractures, and persistent/recurrent lesions are better addressed with surgical procedures. He emphasized the window of opportunity in the inflammatory phase to prevent progression to the destructive burnout phases.1 As with many chronic inflammatory dermatoses, one size does not fit all when deciding flare and maintenance regimens. A combination approach of topicals, antibiotics, anti-hormonal therapies, and immunomodulators, is integral to long-term management. Dr. Daveluy advised setting the expectation that flares will happen, but you’ll work together to watch for trends and adjust the combination regimen accordingly. He recommended the Papaya mobile application as a free tool that patients can use to track their flares.

In addition to flare and maintenance regimens, Dr. Daveluy highlighted the utility of bridge regimens to surgery or targeted biologics. IV/IM ertapenem for 6 weeks1,2 can provide the short-term relief of active inflammation needed to buy time for a surgical intervention with more lasting effects, such as deroofing or sinus tract excision. In certain cases of partial improvement with standard maintenance regimens, short-term adjuncts can make the difference in getting the most of out of the immunomodulators. For example, six to nine months of methotrexate added onto anti-TNF agents can be considered, a strategy shown to maintain serum drug levels in the rheumatoid arthritis setting.3

In conclusion, the management paradigm for HS can be complex with the sheer number of options for various aspects of the multifactorial pathophysiology. Understanding when to dial up medical therapies versus procedural interventions can be crucial to improving outcomes. The pipeline is promising, particularly for new mechanisms of action and dual-target therapies.

References

    1. Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025 Feb 1;405(10476):420-438. Epub 2025 Jan 22. PMID: 39862870.
    2. Segura Palacios JM, Soto Moreno A, Valladares Millán I, Rivas Ruiz F, Cuenca Barrales C, Molina Leyva A. Intramuscular ertapenem for the treatment of severe cases hidradenitis suppurativa. J Dermatolog Treat. 2023 Dec;34(1):2179368. PMID: 36779676.
    3. Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, et al. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol. 2019 Mar;38(3):949-954. PMID: 30402698.

This information was presented by Steven Daveluy, MD at the 2026 ODAC Dermatology Conference. The above highlights from his lecture were written and compiled by Nagasai Adusumilli, MD, MBA.